Extended-release drug formulations for the treatment of epilepsy

作者: Christian Brandt , Theodor W. May

DOI: 10.1080/14656566.2018.1465561

关键词: EpilepsyIn patientExtended releaseDrugIntensive care medicineDrug formulationsPharmacokineticsChildbearing ageTolerabilityMedicine

摘要: INTRODUCTION Extended-release (ER) preparations are either available or have been tested for several antiepileptic drugs (AEDs). Indeed, they may be helpful in improving efficacy, tolerability, adherence, compared to the corresponding immediate release (IR) available. The use of ER has advocated women childbearing age and is - depending on drug especially patients who treated combination with enzyme inducing AEDs as well children. AREAS COVERED Clinical pharmacokinetic studies formulations were identified by a PubMed literature research. Further references added from authors' personal knowledge reference lists studies. Reviews expert commentaries included, where necessary. EXPERT OPINION Unfortunately, providing direct comparisons IR given only handful drugs. short elimination half-life concentration-depending efficacy tolerability.

参考文章(69)
B.J. Steinhoff, H. Stefan, A. Schulze-Bonhage, R. Hueber, W. Paulus, M. Wangemann, C.E. Elger, Retardiertes vs. schnell freisetzendes Oxcarbazepin bei therapierefraktärer fokaler Epilepsie Nervenarzt. ,vol. 83, pp. 1292- 1299 ,(2012) , 10.1007/S00115-012-3598-2
Lawrence J. Lambrecht, Tawfeeq Shekh-Ahmad, Wesley M. Todd, Mark B. Halvorsen, Meir Bialer, Comparative pharmacokinetic analysis of USL255, a new once‐daily extended‐release formulation of topiramate Epilepsia. ,vol. 52, pp. 1877- 1883 ,(2011) , 10.1111/J.1528-1167.2011.03183.X
Annika Sattler, Marion Schaefer, Theodor W. May, Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy Seizure-european Journal of Epilepsy. ,vol. 31, pp. 149- 154 ,(2015) , 10.1016/J.SEIZURE.2015.07.018
Meir Bialer, Patricio Soares-da-Silva, Pharmacokinetics and drug interactions of eslicarbazepine acetate Epilepsia. ,vol. 53, pp. 935- 946 ,(2012) , 10.1111/J.1528-1167.2012.03519.X
A Verrotti, G Nanni, Sergio Agostinelli, ET Alleva, P Aloisi, Emilio Franzoni, A Spalice, Francesco Chiarelli, Giangennaro Coppola, Effects of the abrupt switch from solution to modified‐release granule formulation of valproate Acta Neurologica Scandinavica. ,vol. 125, ,(2012) , 10.1111/J.1600-0404.2011.01568.X
Martin J. Brodie, Scott Mintzer, Alison M. Pack, Barry E. Gidal, Charles J. Vecht, Dieter Schmidt, Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia. ,vol. 54, pp. 11- 27 ,(2013) , 10.1111/J.1528-1167.2012.03671.X
C. Brandt, P. Baumann, G. Eckermann, C. Hiemke, T.W. May, B. Rambeck, B. Pohlmann-Eden, „Therapeutic drug monitoring“ in Epileptologie und Psychiatrie Nervenarzt. ,vol. 79, pp. 167- 174 ,(2008) , 10.1007/S00115-007-2325-X
Theodor W. May, Christian Brandt, Renate Helmer, Christian G. Bien, Willi Cawello, Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy Epilepsia. ,vol. 56, pp. 1134- 1140 ,(2015) , 10.1111/EPI.13022
Gaetano Zaccara, Emilio Perucca, Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disorders. ,vol. 16, pp. 409- 431 ,(2014) , 10.1684/EPD.2014.0714